Provinces, autonomous regions, municipalities directly under the central government, and the Drug Administration of Xinjiang Production and Construction Corps, as well as their respective departments and directly affiliated units:
In order to implement the decision and deployment of the Central Committee of the Communist Party of China and the State Council on carrying out the "Artificial Intelligence+" action, implement the "14th Five Year Plan for National Economic and Social Development of the People's Republic of China and 2035 Vision Goal Outline", "New Generation Artificial Intelligence Development Plan", "Guiding Opinions on Accelerating Scene Innovation and Promoting High level Application of Artificial Intelligence to Promote High quality Economic Development", "14th Five Year Plan for Drug Supervision Network Security and Information Construction" and other work requirements, effectively promote the practical exploration of the "Artificial Intelligence+" action in the field of drug supervision, coordinate the promotion of artificial intelligence scene innovation, and better support high-level supervision and high-quality development, the "List of Typical Application Scenarios of Artificial Intelligence in Drug Supervision" (hereinafter referred to as the "List") is now issued to you. Based on reality, actively explore and implement. The relevant matters are notified as follows:
1、 Work objectives
The "List" lists 15 application scenarios with leading demonstration, development potential, targeted at work pain points, and urgent needs, aiming to promote the research and exploration of artificial intelligence technology in the field of drug regulation, with the main line of promoting the deep integration of artificial intelligence and drug regulation, regulating and guiding drug regulatory departments at all levels to carry out research and application of artificial intelligence technology, guiding resource focus, and promoting the empowerment of the drug regulatory system by artificial intelligence; At the same time, it also provides reference and guidance for other research institutions, technology companies, and pharmaceutical enterprises in related research applications.
2、 Organize and implement
Each unit should fully exert its subjective initiative, combine the current situation of artificial intelligence technology with its own practical work needs, choose the typical application scenarios listed in the "List" as the entry point, and jointly lead the regulatory business department and information technology department of the unit to carry out practical exploration of artificial intelligence application. Encourage various units to collaborate with universities, research institutions, technology enterprises and other entities, adopt flexible and feasible cooperation models, actively seek funding and technical support through various channels, and jointly carry out relevant technology research and implementation work. With the advancement of artificial intelligence technology and the development of regulatory integration applications in the later stage, various units can further research and explore new application scenarios, and provide feedback to the Cyberspace Administration of China to gradually expand the content of the "List".
When carrying out practical work on artificial intelligence applications, each unit should also pay attention to network security and data security issues. Based on the classification and grading protection requirements of regulatory data resources involved in artificial intelligence models and the computing power requirements of artificial intelligence computing models, appropriate application deployment plans should be selected, system and data access permissions should be reasonably set, data leakage and abuse risks should be avoided, and the safe and stable application and development of artificial intelligence technology in the field of drug supervision should be ensured.
The Cyberspace Administration of China will timely collect a batch of typical application scenario projects with demonstration and leading effects that can be replicated and promoted as typical cases of smart supervision or demonstration projects of drug smart supervision for demonstration and promotion.

Comprehensive Department of the National Medical Products Administration
June 13, 2024